Biolexis Therapeutics Advances Breakthrough GLP-1 and AMPK Programs into First-in-Human Clinical Trials
Groundbreaking Preclinical Data Propel Clinical Milestone
Posted in BioUtah News
Tagged Biolexis
Comments Off on Biolexis Therapeutics Advances Breakthrough GLP-1 and AMPK Programs into First-in-Human Clinical Trials
Biolexis Therapeutics launches subsidiary Metabolexis to develop novel oral medicines for Obesity and Type 2 Diabetes to improve human longevity
Metabolexis focuses on GLP-1 weight loss and type 2 diabetic drug discoveries to improve accessibility and meet unprecedented demand.
Posted in BioUtah News
Tagged Biolexis
Comments Off on Biolexis Therapeutics launches subsidiary Metabolexis to develop novel oral medicines for Obesity and Type 2 Diabetes to improve human longevity
Biolexis Secures $10 Million in Series A Funding to Advance Metabolic Drug Development
LED BY CLARKE CAPITAL, THE NEW FUNDING ROUND WILL ACCELERATE THE COMPANY’S DRUG DISCOVERY PIPELINE
Posted in BioUtah News
Tagged Biolexis
Comments Off on Biolexis Secures $10 Million in Series A Funding to Advance Metabolic Drug Development
